| Next 10 |
Ad
ASND News and Press Ascendis Pharma A/S
-
U.S.-listed shares of Ascendis Pharma ( ASND ) gained 7% to $101.82, after the Danish biotech reported Q2 results that beat estimates, helped by a surge in sales of growth hormone drug Skytrofa. ASND posted Q2 GAAP EPS of -€1.46 which beat expectations by ...
-
Ascendis Pharma A/S (ASND) Q2 2022 Earnings Conference Call August 10, 2022 16:30 ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott Smith - Senior Vice President and Chief Financial O...
-
Ascendis Pharma press release ( ASND ): Q2 GAAP EPS of -€1.46 beats by €0.69 . Revenue of €6.16B (+503.9% Y/Y) beats by €6.15B . For further details see: Ascendis Pharma GAAP EPS of -€1.46 beats by €0.69, revenue...
-
— U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacement therapy, on track for Q3 2022; EU submission planned for Q4 2022 — SKYTROFA revenue continued to double quarter-to-quarter, reaching Ȋ...
-
Ascendis Pharma ( ASND ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, after market close. The consensus EPS Estimate is -$2.30 and the consensus Revenue Estimate is $5.93M (-99.4% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revi...
-
COPENHAGEN, Denmark, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, August 10, 2022, at 4:30 p.m. Eastern Time (ET) to review its second quarter 2022 financial results and provi...
-
Look for surprise values in underpriced stocks. Not the story issues being bally-hooed by touts and the media – everyone knows them. Experienced professional researchers know the details of industry issues and their hidden values and special strengths. They know when to add...
-
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
-
– Late-breaker oral presentation of TransCon PTH Phase 3 PaTHway Trial data in adult hypoparathyroidism on Tuesday, June 14 – Oral presentation of TransCon PTH Phase 2 PaTH Forward Trial Open-Label Extension Data in adult hypoparathyroidism on ...
-
- Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology - Scott A. Holmes has been appointed to the newly created role of Head of Global Commercial Strategy, Endocrinology - Jesper Høiland, Global Chief Comm...
Stock Information
MENU
ASND
ASND Quote
ASND Short
ASND News
ASND Articles
Get ASND Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
Ad
-
— U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacement therapy, on track for Q3 2022; EU submission planned for Q4 2022 — SKYTROFA revenue continued to double quarter-to-quarter, reaching Ȋ...
-
COPENHAGEN, Denmark, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, August 10, 2022, at 4:30 p.m. Eastern Time (ET) to review its second quarter 2022 financial results and provi...
-
– Late-breaker oral presentation of TransCon PTH Phase 3 PaTHway Trial data in adult hypoparathyroidism on Tuesday, June 14 – Oral presentation of TransCon PTH Phase 2 PaTH Forward Trial Open-Label Extension Data in adult hypoparathyroidism on ...
x
Ad
